Myezom 2 mg

Myezom is a medication used to treat multiple myeloma, a type of cancer that affects the bone marrow. It is an intravenous injection that works by inhibiting the activity of enzymes called proteasomes, which are involved in the breakdown of proteins and help cancer cells grow and survive.

Composition:

Myezom contains Bortezomib, a medication that is a proteasome inhibitor.

Indications:

Myezom is indicated for the treatment of:

1. Multiple myeloma in patients who have received at least one prior therapy
2. Mantle cell lymphoma in patients who have received at least one prior therapy

Mechanism of Action:

Bortezomib works by:

1. Inhibiting the activity of proteasomes, which are involved in the breakdown of proteins and help cancer cells grow and survive
2. Reducing the production of proteins that promote cancer cell growth and survival

Dosage and Administration:

The recommended dosage of Myezom is:

• 1.3 mg/m2 administered intravenously over 3-5 seconds every 2 weeks
• The dose should be adjusted based on the patient’s response to treatment and tolerability

Side Effects:

Common side effects of Myezom include:

1. Nausea and vomiting
2. Diarrhea
3. Fatigue
4. Thrombocytopenia (low platelet count)
5. Neutropenia (low white blood cell count)
6. Peripheral neuropathy (nerve damage)

Serious side effects can include:

1. Neurotoxicity (nerve damage)
2. Cardiac arrhythmias
3. Hypertension (high blood pressure)
4. Respiratory depression
5. Severe allergic reactions

Contraindications:

Myezom is contraindicated in patients with:

1. Hypersensitivity to Bortezomib or other proteasome inhibitors
2. Severe liver disease
3. Severe kidney disease

Precautions:

1. Patients with a history of cardiovascular disease should be closely monitored while receiving Myezom.
2. Patients with a history of liver disease should be closely monitored while receiving Myezom.
3. Patients with a history of kidney disease should be closely monitored while receiving Myezom.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of nausea or vomiting.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store at room temperature (20°C to 25°C) and protected from light.
• Do not freeze or expose to direct sunlight.
• Use within 24 months of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.